Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortDual-action anti-VEGF/anti-Ang-2 eye injection with longer intervals.Sight-saving eye injection for wet macular degeneration.
Body systemEyesEyes
Drug classAnti-VEGF injectionsAnti-VEGF injections
SupplyPrescription onlyPrescription only
Main usesWet age-related macular degeneration, Diabetic macular oedema, Retinal vein occlusionWet age-related macular degeneration, Diabetic macular oedema, Retinal vein occlusion
How it worksStops abnormal blood vessels leaking in the retina, for longer between injections.Blocks the signal that grows leaky vessels at the back of the eye.
Starts workingWeeks—
Half-lifeAbout 7.5 days—
Typical adult dose6 mg injected into the eye every 4 weeks for 4 doses, then every 8–16 weeks.2 mg monthly for 3 months, then every 8–16 weeks (8 mg high-dose can extend further).
FormsIntravitreal injectionIntravitreal injection
Common side effectsEye redness, Floaters, Eye pain, Raised eye pressureEye redness, Floaters, Eye pain
Serious side effectsEndophthalmitis, Retinal detachment, Retinal tearsEye infection (endophthalmitis), Retinal detachment, Raised eye pressure
Don't take ifActive eye infection; Active intraocular inflammation—
AlcoholUsually no problem in moderation. No specific interaction.—
PregnancyUse with cautionLimited data; specialist decision.Usually avoidedNot recommended.
BreastfeedingUse with cautionLimited data.—
In use since—2011
Brand namesUnited States: VabysmoUnited Kingdom: VabysmoIndia: VabysmoUnited States: Eylea, Eylea HDUnited Kingdom: EyleaIndia: Eylea
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H—
ATC codeS01LA09S01LA05

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker